The market for new antibiotics is effectively failing. No novel class of drugs for the most virulent and persistent infections, those caused by Gram negative bacteria, has entered the clinic for over 50 years, and the drugs we have are steadily, if slowly, becoming less effective. Earlier this year Dame Sally Davies, the outgoing Chief Medical Officer for England, described the threat of antibiotic resistance as ‘catastrophic’ and potentially as great as that from climate change.
BI (Business Intelligence) is a set of processes, architectures, and technologies that convert raw data into meaningful information that drives profitable business actions. It is a suite of software and services to transform data into actionable intelligence and knowledge.
Cambridge Antibody Technology has been described as the ‘jewel in the crown’ of the UK biotech industry; it is certainly one of our region’s principal success stories. This company, originally known as CAT, was founded in 1989 to take advantage of phage display technology for the development of antibody therapeutics. Following worldwide success with the blockbuster anti-TNF antibody adalimumab (Humira™) it was acquired by AstraZeneca in 2006 and now forms part of that company’s biologics subsidiary.
When it comes to influencing prospective customers in the life science sector, outbound marketing approaches such as cold calling, banner ads and unsolicited emails are no longer delivering a return on investment like they used to. Poorly targeted and relatively expensive, these once tried-and-tested tactics are increasingly delivering disappointing results. As marketers, if we want to continue to engage with modern scientific audiences, it’s vital that we adapt to be successful.
Whatsapp, Youtube, Google Ads, Linkedin, Facebook, Instagram, Twitter, e-mail, Teams, Skype, Slack… it’s easy to feel the dread and anxiety when glancing at your phone on an afternoon! All these platforms have one thing in common: your attention!
Even scientific brands have now joined the incessant competition for your attention. So how do you separate the signal from the noise in this increasingly competitive world?
Disaster can strike at any moment, but where do you start to put things right when the worst happens and fire ravages your priceless research, expensive equipment and impacts thousands of your patients who depend on the lab work for life-saving medical treatment?
It’s no secret that life science tradeshows can provide an invaluable opportunity to raise your profile and boost awareness of your latest offering. However, these events can also consume substantial amounts of budget – including booth set-up costs, sponsorship fees and travel expenses, not to mention a significant chunk of your team’s time. So, how can you make sure you secure a good return on your investment?
We are seeing an era of change by the Global regulatory bodies for Pharmaceuticals, Medical devices and in-vitro diagnostics - and companies in the Life Sciences sector are working overtime to understand and adopt this brand new world.
While the companies in the US are facing regulatory headwinds on Patient safety, the EU region is shaking the world with the new MDR and IVDR guidelines.
The overall intent is good but the journey towards bringing this change is going to disrupt a lot of companies in the way.
Digital Marketing and Life Sciences are more similar than you might think.
Both are multi-billion dollar industries that use testing and logic to prove hypotheses. Both markets use big data sets, whether it’s recording vast experimental results or simply organising the world’s information online.
The simplest similarity, however, is the enormous growth potential of both SEO and Life Sciences.